congress - european renal association

59TH

ERACONGRESSPARIS & VIRTUAL

MAY 19-22, 2022

INDUSTRYSYMPOSIA

BOOKLET

59TH


MAY 19-22, 2022

2

INDUSTRY SYMPOSIA BOOKLET20MAY

13:30|14:30 ROOM SESSION SESSION TITLE

HALL N01 ISS 1.10

Lupus nephritis: can we preserve kidney function?Current challenges and practical considerations

HALL N02 ISS 1.11

Transforming care in ANCA Vasculitis (GPA/MPA):An alternative approach to reduce relapses and glucocorticoid use

HALL N03 ISS 1.12Overcoming DSA Barriers to Transplant

HALL N04 ISS 1.13Applying genetics in your kidney practice

HALL S01 ISS 1.14Proteinuria in FSGS and IgA Nephropathy & The Dual Roleof ET-1 and Ang II

HALL S02 ISS 1.17

Rethinking the role of nephrologists in prevention of CKD The opportunity of early risk identification

HALL S03 ISS 1.15

APOL1-mediated kidney disease (AMKD):A genetically-driven proteinuric glomerular nephropathy

VIRTUAL HALL 1 ISS 1.16 Closing the loop with SGLT2 inhibitors for CKD management

VIRTUAL HALL 2 ISS 1.18

Uncovering genetic causes of CKD and managing Primary Hyperoxaluria Type 1: An update on recent advances


HALL N01 ISS 1.1PD - safer at home: growing and maintaining home dialysis programs

HALL N02 ISS 1.2 The future of anemia of CKD: Where are we going?

HALL N03 ISS 1.3

Targeting the alternative complement pathway in IgA nephropathy and C3 glomerulopathy: clinical and therapeutic perspectives

HALL N04 ISS 1.4Emerging treatment options in CKD & T2D: are GLP-1RAs next? - A discussion

HALL S01 ISS 1.5 An important renal biomarker: Proteinuria

HALL S02 ISS 1.7 Innovations for patient-centered care in dialysis

HALL S03 ISS 1.6Ensuring optimal RAASi therapyin patients with hyperkalemia:An interdisciplinary approach

VIRTUAL HALL 1 ISS 1.8 Adsorption: The new frontierfor blood purification

VIRTUAL HALL 2 ISS 1.9What’s new in FSGS & IgAN: Classroom to Clinic™

59TH


MAY 19-22, 2022

3

INDUSTRY SYMPOSIA BOOKLET


HALL N01 ISS 2.1Preventing CKD in patients with Diabetes Exploring the currentand future role of GLP-1RA

HALL N02 ISS 2.2 Blood purification: apheresis, dialysis and beyond

HALL N03 ISS 2.3MCO Delivering HDx Therapy: Improving Clinical and Economic outcomes in the real world

HALL N04 ISS 2.4A shift in focus: International insights into the optimal management of CKD-MBD

HALL S01 ISS 2.5Looking beyond K+in hyperkalemia for cardio-renal protection

HALL S02 ISS 2.7 Innovative Treatment Strategies for Haemodialysis and Hypertension

HALL S03 ISS 2.6 A gutsy new approach to delaythe progression of IgAN

VIRTUAL HALL 1 ISS 2.8À la carte Hemodialysis for Patient: PMMA Adsorptive Membrane


HALL N01 ISS 2.10Kidney disease and COVID-19: addressing challenges to protect the vulnerable

HALL N02 ISS 2.11

Nonsteroidal MRAs: A new hope for improved cardiorenal outcomes in patients with CKD and T2D

HALL N03 ISS 2.12

The burden and management of symptoms in chronic kidney disease (CKD) patients on haemodialysis: an insight into CKD-associated pruritus

HALL N04 ISS 2.13HIF-PH inhibition: Simplicity through innovation for adult patients with anaemia of CKD

HALL S01 ISS 2.14Managing female patients with Fabry disease – the relevance of the XX factor

HALL S02 ISS 2.16

How can the multidisciplinary care improve the patients’ journey in inherited rare diseases. The importance of nephrologist as coordinator.

HALL S03 ISS 2.15 Diagnosis and Management of aHUS: Time is of the Essence

VIRTUAL HALL 1 ISS 2.17 The multiple faces of ANCA vasculitis

VIRTUAL HALL 2 ISS 2.18Introducing Nipro’s novel super high flux sharp cut-off dialyzer

21MAY

59TH


MAY 19-22, 2022

4


20 May 2022 9:45 – 10:45 am

For more information visit us at our booth A240

JOIN OUR SYMPOSIUM

PD – safer at home: growing and maintaininghome dialysis programs

20 May 2022 9:45 – 10:45 am

5 min

15 min

15 min

15 min

10 min

INTRODUCTION

Experience during Covid-19

Remote Patient Management

Getting EU Health Systems to be home centric

Q&A

Prof. Vladimir Tesar, MD, PhD

Prof. Edwina Brown, MD, FRCP

Dr. Annabel Boyer, MD

Prof. Raymond Vanholder, MD PhD

All

Time Topic Speaker

Interprofessional care management models, fostering the collaboration between nurses and physicians can have a positive impact on the provision of healthcare and on patient outcomes. The objective of this symposium is to present the physician’s, the nurse’s and the patient’s point of view in the context of a patient centric peritoneal-dialysis (PD) therapy. While all three stakeholders have the same overarching goal; to improve survival, to reduce complications and to improve patient’s quality of life, their clinical needs during the patient pathway and episode of care might be slightly different.

Furthermore, the unprecedented events related to the spread of Global Pandemic of Furthermore, the unprecedented events related to the spread of Global Pandemic of Covid-19, have highlighted the key impact of home treatment implementation on patient safety, resource optimization, organizational models and rate of hospitalizations and complications management with relative impact on their costs. Consequently, this worldwide experience prioritizes the focus on how most patients could be treated with home PD. This provides advantages for patients, clinical staff, and caregivers as well as health systems overall, by being in-home centric.

The aim of this symposium is to share how, as it has been demonstrated, most dialysis The aim of this symposium is to share how, as it has been demonstrated, most dialysis patients could be treated more efficiently at home with PD compared with what has been considered so far.

EMA-RC00-220008

PD – safer at home: growing and maintaininghome dialysis programs

https://vmx.m-anage.com/eraedta/era22/en-GB/session/84700

59TH


MAY 19-22, 2022

5


GSK is delighted to invite you to attend our symposium at ERA 2022 titled The future of anemia of CKD: Where are we going?

The latest on the underlying mechanism

Prof. Christoph WannerProfessor of Medicine and head of the Division of Nephrology at the University Hospital of Würzburg, Germany

When to treat, why, and challenges of management

Prof. Kirsten JohansenDirector of Nephrology and Co-director of the Chronic Disease Research Group at Hennepin Healthcare, US

Chair

Prof. Sunil BhandariConsultant Nephrologist, Hull University Teaching Hospitals NHS Trust, UK

Honorary Clinical Professor at the Hull York Medical School, UK

Friday, 20th May 2022 | 09:45–10:45 CET

Available in person, live streamed and on demandFor Healthcare Professionals Only Trade marks are owned by or licensed to the GSK group of companies ©2022 GSK group of companies or its licensor

NX-GBL-DPR-ADVT-220003Date of preparation: April 2022

Q&A

All faculty membersModerator: Prof. Sunil Bhandari


59TH


MAY 19-22, 2022

6


Targeting the alternative complement pathway in IgA nephropathy and C3 glomerulopathy: clinical and therapeutic perspectives

Novartis-sponsored symposium (Live)

9:45 Welcome noteCo-chairs:Giuseppe Remuzzi, Jürgen Floege

9:50 A clinical perspective on the evolving therapeutic strategy for IgAN Smeeta Sinha Moderated by: Jürgen Floege

10:05 C3G in the spotlight – a clinical and therapeutic overviewVeronique Frémeaux-Bacchi, Moglie Le Quintrec-DonnetteModerated by: Giuseppe Remuzzi

10:30 Live audience Q&AAll facultyModerated by: Jürgen Floege

10:40 Closing noteCo-chairs

Agenda

Welcome from the co-ChairsIt is our great pleasure to welcome you to the Novartis-sponsored symposium at ERA 2022, where we will examine current challenges in the management of patients with IgA nephropathy (IgAN) and C3 glomerulopathy (C3G), and highlight recent therapeutic advances. Our expert faculty will explore these topics via clinical case presentations and engaging panel discussions, and we warmly encourage your active participation during the Q&A session. We hope you enjoy what will be an interesting and informative session.

Giuseppe Remuzzi Jürgen FloegeMario Negri Institute for Pharmacological Research, University Hospital Aachen, Milan, Italy Aachen, Germany

Please scan the QR code to download the delegate brochure to your phone

FUSE MLR ID: 201283 | Approval April 2022

Novartis Pharma AG© 2022 Novartis Pharma AG, CH-4002 Basel, Switzerland

Novartis is committed to patients living with complement-mediated kidney diseases, to bring transformative medicines that can potentially slow disease progression and extend dialysis-free life in these patients.

Introducing our expert faculty

Giuseppe Remuzzi, Mario Negri Institute for Pharmacological Research, Milan, Italy

Smeeta Sinha, Salford Royal NHS Foundation Trust, Salford, UK

Jürgen Floege, University Hospital Aachen, Aachen, Germany

Veronique Frémeaux-Bacchi, European Hospital Georges Pompidou, Paris, France

Moglie Le Quintrec-Donnette, University Hospital of Montpellier, Montpellier, France

Friday, 20 May 2022 | 09:45–10:45 CEST | ERA Congress 2022Paris Expo Porte de Versailles, Paris, France

Hall N03


59TH


MAY 19-22, 2022

7


ERA 2022 Novo Nordisk symposium

Emerging treatment options in CKD & T2D: are GLP-1 RAs next? - A discussion

This symposium is organised and funded by Novo Nordisk.Novo Nordisk products will be discussed.

May 20th 2022, 9:45-10:45 (CET)F2F meeting

Dear colleagues,

On behalf of our esteemed faculty, I am delighted to invite you to the Novo Nordisk industry symposium entitled “Emerging treatment options in CKD & T2D: are GLP-1 RAs next?”. In keeping with the hybrid format of the ERA 2022 Annual Congress, the symposium will be held face-to-face in Paris, on Friday 20th May at 9:45-10:45 (CET), as well as broadcast live online

Diabetes is the leading cause of chronic kidney disease (CKD) worldwide, with estimates that as many as 40% of patients with diabetes will develop CKD. GLP-1 RAs are known to be effective glucose-lowering agents for people with T2D, which also provide weight reduction and cardiovascular benefits. Data from recent clinical trials indicate that they remain safe and effective in people with kidney impairment.

In this symposium, we aim to increase understanding of the role of GLP-1 RAs in treating people with CKD & T2D, through a mix of short presentations and roundtable discussions. These bite-sized sessions will focus on the rapidly evolving treatment landscape for CKD in T2D, the current evidence related to GLP-1 RAs in people with CKD and T2D, as well as reflection on what the future might hold for the class.

I look forward to your participation in this informative and engaging symposium.

Peter Rossing, MD, DMScProfessor, Steno Diabetes Center Copenhagen,University of Copenhagen, Denmark

ERA 2022 Novo Nordisk symposium

Emerging treatment options in CKD & T2D: are GLP-1 RAs next? - A discussion

05 mins Welcome and introduction (chair)Prof. Peter Rossing

15 mins The Changing Treatment Landscape for CKD in T2DPresentation + Roundtable discussion (incl. Q&A)Dr. Maria Jose Soler

15 mins Current Evidence for GLP-1 RAs for CKD in T2DPresentation + Roundtable discussion (incl. Q&A) Dr. Ofri Mosenzon

22 mins What might the future hold for GLP-1 RAs in CKD & T2D?Presentation + Roundtable discussion (incl. Q&A) Prof. Hiddo Heerspink

03 mins Closing remarks Prof. Peter Rossing


59TH


MAY 19-22, 2022

8


A non-promotional, educational symposium organised and funded by Otsuka Pharmaceutical Europe Ltd,

intended for Healthcare Professionals only

Introducing the faculty59th European Renal Association (ERA) CongressParis, France (and virtual option will be available)

An important renal biomarker: proteinuria

09:45 Introduction Noémie Jourde-Chiche

09:55Proteinuria as a surrogate endpoint in clinical trials: past and present

Kieran McCafferty

10:15Other clinical trial endpoints used in nephrology

Patrick Mark

10:35 Q&A All faculty

10:40 Closing summary Noémie Jourde-Chiche

Programme

Friday 20th May 20229:45–10:45 (CET)

Room S01, Level 7.3, Paris Convention Centre(Virtual option will be available)

ChairProfessor Noémie Jourde-Chiche Aix-Marseille University Marseille, France

SpeakersDr Kieran McCafferty Barts Health NHS Trust London, UK

Professor Patrick Mark Queen Elizabeth University Hospital Glasgow, UK

Overview

This non-promotional, educational symposium will explore the evolving role of proteinuria as a surrogate endpoint in clinical trials and consider whether reduction in proteinuria is clinically meaningful in patients with kidney disease.

Other clinical endpoints used in nephrology trials, the emergence of new endpoints and their potential impact in the clinical setting will also be discussed.

Dr Kieran McCafferty

Dr McCafferty is Consultant Nephrologist at Barts Health NHS Trust and Honorary Senior Lecturer at Queen Mary University of London, UK.

Since 2015, Dr McCafferty has led 44 clinical trials at these institutions and has been the national lead on four National Institute for Health Research landmark international interventional studies. He has been an invited speaker and lecturer at meetings in Europe, North America and Asia. Dr McCafferty is currently Co-Chair of the UK Kidney Research Consortium Chronic Kidney Disease and Diabetes Clinical Study Group and has authored over 30 peer-reviewed publications in the field.

Professor Patrick Mark

Professor Mark is Clinical Professor of Nephrology and Honorary Consultant Nephrologist at Queen Elizabeth University Hospital, Glasgow and the University of Glasgow, UK.

His research focuses on the cardiovascular complications of chronic kidney disease (CKD) and novel applications of imaging in CKD, and he has served on the steering committees of several pivotal clinical trials. Professor Mark is an author on more than 190 peer-reviewed pubications, a reviewer for over 20 high-impact journals, and a current member of the European Renal Association EUropean REnal and CArdiovascular Medicine (EURECA-m) Working Group.

Professor Noémie Jourde-Chiche

Professor Jourde-Chiche is Professor of Nephrology at Aix-Marseille University, Marseille, France.

Her research focuses on lupus nephritis, renal vasculitis, renal amyloidosis, endothelial dysfunction and biomarker discovery. She has served as Principal Investigator on six clinical trials and is an author on over 130 peer-reviewed publications. She is also an elected member of the Research Commission, the Clinical Nephrology Commission of the the Société Francophone de Néphrologie Dialyse et Transplantation (SFNDT), and is a member of several local committees including the Groupe Coopératif sur le Lupus Rénal and the Groupe Français d’Etude des Vascularites.

OPE-NEP-2200004 | Date of Preparation: May 2022 | For healthcare professional use only.


59TH


MAY 19-22, 2022

9


Head office : Fresenius Medical Care Deutschland GmbH 61346 Bad Homburg v. d. H. · Germany · Phone : +49 (0) 6172-609-0

www.freseniusmedicalcare.com

Innovations for patient-centered care in dialysis

59th ERA Congress

Hemodialysis: New perspectives for reducing complexity in daily practice Jeroen Kooman, Netherlands

Home Dialysis: Technologies for high-quality goal-directed home dialysis Neill Duncan, United Kingdom

Chair: Len Usvyat, USA and Christian Combe, France

Industry Symposium Friday, May 20, 2022 · 09:45 – 10:45 a.m.


59TH


MAY 19-22, 2022

10


Ensuring optimal RAASi therapy in patients with hyperkalemia: An interdisciplinary approach

Friday, May 20, 2022, 09:45–10:45 CEST

Chair’s introductionProfessor David Wheeler

Consequences of hyperkalemia on optimal RAASi therapyDr Lucia Del Vecchio

!

Challenges for primary care physicians in the treatment of hyperkalemia: importance of practical treatmentsProfessor David Wheeler

Enabling long-term RAASi therapy in patients with hyperkalemia: The role of novel potassium bindersProfessor Patrick Rossignol

Panel discussion, Q&A and closeAll faculty

Document number: FR-PAT-2200010; Date of preparation: March 2022This industry symposium is sponsored and organized by Vifor Pharma. The ERA assumes no responsibility for the information published in this document.


59TH


MAY 19-22, 2022

11


Time (CEST) Presentation Speaker(s)

09:45 Welcome, pre-symposium test, and Chair’s opening remarks Sharon Adler

09:50 Plenary 1 Pathogenesis, risk prediction, and the role of proteinuria in FSGS and IgAN

Moin Saleem and Jonathan Barratt

10:05 Plenary 2 Improving management of FSGS and IgAN: Current best practice and future therapies


10:20 Workshop 1 Quiz: Awareness and diagnosis of FSGS and IgAN Moin Saleem and Jonathan Barratt

10:25 Workshop 2 Case studies: Management of FSGS and IgAN in practice


10:35 Q&A All

10:40 Chair’s close and post-symposium test Sharon Adler

FACULTY

AGENDA

What’s new in FSGS and IgAN: Classroom to Clinic™Virtual symposium on Friday, 20 May @ 09:45 CEST Registration links will be made available via the congress website at the end of April. Screens will be set up at the congress centre for any on-site delegates that wish to attend.

This symposium has been funded by an arms-length educational grant from Travere Therapeutics. The content has been developed by the faculty in collaboration with Liberum IME. Travere Therapeutics. has had no influence on the content or faculty selection.

An application has been made to the UEMS EACCME® for CME accreditation of this event.

Liberum IME is an independent medical education agency that creates bespoke, innovative programs that follow the core principles of good CME practice. We are dedicated to sharing best practice through international collaboration, allowing healthcare professionals worldwide to put science into practice.CME, continuing medical education; EACCME, European Accreditation Council for Continuing Medical Education; FSGS, Focal segmental glomerulosclerosis; IgAN, Immunoglobulin A Nephropathy; UEMS, European Union of Medical Specialists

An interactive symposium with accredited training materials to take awayThis symposium will provide an update on the pathophysiology and management of FSGS and IgAN through plenary presentations and interactive workshops from the Classroom to Clinic™ programme.

What is Classroom to Clinic™?Classroom to Clinic™ is an international CME-accredited programme designed to facilitate small-group training workshops in FSGS and IgAN, Chaired by Professor Sharon Adler. Attendees will receive a link to access these free, accredited resources to use with colleagues.

Join us to find out more

CHAIR SPEAKERS

Professor Sharon Adler, Harbor-UCLA Medical Center,

Los Angeles, USA

Professor Jonathan Barratt, Leicester General Hospital,

Leicester, UK

Professor Moin Saleem, Bristol Children’s Hospital,

Bristol, UK

Learning objectivesAfter attending this symposium, attendees will be able to:

1 Describe the burden and need to consider FSGS and IgAN in patients with proteinuria and/or hematuria, and the importance of collaboration and/or referral to obtain an accurate and timely diagnosis

2 Explain the distinct pathogenesis of IgAN and differing forms of FSGS, including the implications of proteinuria, and the need to treat to clinically meaningful proteinuria targets

3 Discuss safety and efficacy data and mechanism of action of current and potential new treatments

4 Utilise guideline recommendations to optimise disease management decisions in FSGS and IgAN


59TH


MAY 19-22, 2022

12


Lupus nephritis: can we preserve kidney function?Current challenges and practical considerationsCurrent challenges and practical considerations

Friday 20th May 2022, 13:30–14:30 CEST, Room N01In person, live-streamed and on demandIn person, live-streamed and on demand

For Healthcare Professionals PM-GBL-BEL-BKLT-220001 Date of preparation: March 2022

Agenda

Welcome and introductory remarks Professor Liz Lightstone, UK (Chair)

How can we help to preserve kidney function in lupus nephritis? Professor Hans-Joachim Anders, Germany Discussion (All faculty)

Closing remarks Professor Liz Lightstone, UK (Chair)

Targeted B-cell therapies in lupus nephritis: what do we know so far? Professor Enrique Morales, Spain Discussion (All faculty)

A GSK-sponsored and -organised symposium at ERA 2022. Prescribing information for all GSK products discussed will be available at this symposium.


59TH


MAY 19-22, 2022

13


Friday May 20th 13.30-14.30 CET

Live Symposium in Hall N02held during the 59th ERA Congress

HQ-AVA-2200049Date of approval March 2022

Live Symposium in Hall N02held during the 59th ERA Congress Transforming care in ANCA

vasculitis (GPA/MPA): An alternative approach to reduce

relapses and glucocorticoid useChair: Prof. Benjamin Terrier

University of Paris and Hôpital Cochin, Paris, France

AGENDA

13.40 First in class treatment1 targeting the complement systemProf. David Jayne, University of Cambridge and Addenbrooke’s Hospital, Cambridge, UK

14.00 Assessing kidney function and glucocorticoids need: When – How - Why?Prof. Annette Bruchfeld, Linköping University and Karolinska Institutet, Stockholm, Sweden

14.20-14.30 Q&A and Closing remarksProf. Benjamin Terrier

13.30 Welcome and introductionsProf. Benjamin Terrier

13.35 Unmet medical need in ANCA vasculitis and patient burdenProf. Benjamin Terrier

1European Medicines Agency Press Release November 12 2021. Available at https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Last accessed March 2022.


59TH


MAY 19-22, 2022

14



59TH


MAY 19-22, 2022

15


Applying genetics in your kidney practice

Featuring presentations by

Friday 20th May 2022 | 13:30–14:30 (CET) | Room N04

Welcome Prof Bertrand Knebelmann

APOL1 Nephropathy: From discovery to clinical applications Prof David Friedman

Alport Syndrome: From bench to bedside Prof Rachel Lennon

Questions and answers All

Prof Bertrand Knebelmann

Prof David Friedman

Prof Rachel Lennon

This symposium is sponsored by Sanofi and is intended for healthcare professionals only.Copyright © 2022 Sanofi. All rights reserved.MAT-GLB-2200964 (v1.0) | April 2022


59TH


MAY 19-22, 2022

16


Travere Therapeutics-sponsored symposium at the 59th ERA-EDTA Congress, May 19-22, 2022, Paris, France

Proteinuria in FSGS and IgA Nephropathy & The Dual Role of ET-1 and Ang IIFriday 20 May 2022, 13:30–14:30 CEST Room S01 (and available to stream online)

Agenda:Welcome and Housekeeping Pierre-Louis Tharaux

Spotlight on IgA Nephropathy – Clinical Significance of Proteinuria Loreto Gesualdo

Spotlight on FSGS – Clinical Significance of Proteinuria Sian Griffin

Evidence For the Dual Role of ET-1 and Ang II in Proteinuria and CKD Progression in IgA Nephropathy and FSGS Pierre-Louis Tharaux

Your Questions Answered – Panel Discussion and Q&A Moderated by Pierre-Louis Tharaux

© 2022 Travere Therapeutics, Inc. All rights reserved. April 2022 – MA-SP-22-0068

Prof. Pierre-Louis Tharaux Paris, France (Chair)

Dr. Sian GriffinCardiff, UK

Prof. Loreto GesualdoBari, Italy

Speakers


59TH


MAY 19-22, 2022

17


EBAC-ACCREDITED SYMPOSIUM TO BE HELD DURING ERA 2022, PARIS, FRANCE & VIRTUAL

AGENDA13:30 – 13:35 Introduction:

Barriers for preventing CKD in patients with diabetes:

How can we do better?

Christoph Wanner, MD – Würzburg, Germany

13:35 – 13:50 Early screening and risk identification of CKD in patients with

diabetes: Why is it so important?

Rikke Borg, MD – Roskilde, Denmark

13:50 – 14:05 Primary care as gatekeeper in CKD:

The need for collaboration with nephrologists

Kamlesh Khunti, MD – Leicester, United Kingdom

14:05 – 14:30 Rethinking roles and responsibilities in prevention

of CKD in diabetes

All faculty

FRIDAY, MAY 20, 2022 | 13:30 – 14:30 HRS | HALL S02Supported by an unrestricted educational grant from Boehringer Ingelheim and Lilly Alliance.The scientific programme has not been influenced in any way by

its sponsors.

“In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which

might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant

to the event are declared to the audience prior to the CME activities.”

Rethinking the role of nephrologists in prevention

of CKD – The opportunity of early risk identification


59TH


MAY 19-22, 2022

18


Please join us at the Vertex-sponsored and organized symposium entitled

at the 59th European Renal Association Congress

Speaker: Aude Servais, M.D., Ph.D.

We look forward to seeing you there!

Senior Nephrologist, Necker University Hospital, Paris Cité University, France

This presentation is organised and fully funded by Vertex Pharmaceuticals IncorporatedThis presentation is organised and fully funded by Vertex Pharmaceuticals Incorporated©2022 Vertex Pharmaceuticals Incorporated | INT-02-2200062 (v 1.0) | 04/2022©2022 Vertex Pharmaceuticals Incorporated | INT-02-2200062 (v 1.0) | 04/2022

APOL1-MEDIATED KIDNEY DISEASE: A GENETICALLY-DRIVEN PROTEINURIC

GLOMERULAR NEPHROPATHY

Date: Friday, 20 May 2022Time: 13:30–14:30 CET

Location: Room S03, Paris Expo Porte de Versailles, Paris, France

For healthcare professionals only


59TH


MAY 19-22, 2022

19


Friday 20 May 202213:30–14:30 CESTJoin Kieran McCafferty and colleagues as they discuss the important role of the nephrologist in the MDT setting and provide practical advice on identifying patients most likely to benefit from SGLT2 inhibitors.

INDEPENDENT VIRTUAL SYMPOSIUM

Chaired by Kieran McCafferty with Adeera Levin & Beatriz Fernández-Fernández

After participating in the symposium, you will be able to:

• Describe the importance of a clear approach to optimize care for CKD patients

• Identify CKD patients who would most benefit from SGLT2 inhibitor therapy

• Debate the nephrologist’s role in the MDT – elevating the importance of addressing CKD and leading synergized and optimized patient care.

LEARNING OBJECTIVES

AGENDA

13:30 Welcome & introduction Dr Kieran McCafferty (Chair)Barts Health NHS Trust, UK

13:40 Why & how should we optimize care for patients with CKD?

Dr Adeera LevinUniversity of British Columbia, Canada

13:55 In which patients should we use SGLT2 inhibitors?

Dr Beatriz Fernández-FernándezFundación Jiménez Díaz University Hospital Health Research Institute, Spain

14:15 Faculty Q&A All

14:30 Summary & close Dr Kieran McCafferty

AstraZeneca has provided an educational grant towards this independent program.

The symposium Closing the loop with SGLT2 inhibitors for CKD management, Paris, France, 20/05/2022-20/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.


59TH


MAY 19-22, 2022

20


UNCOVERING GENETIC CAUSES OF CKD AND MANAGING PRIMARY HYPEROXALURIA TYPE 1: AN UPDATE ON RECENT ADVANCES

FOR HEALTHCARE PROFESSIONALS ONLY.

YOU WILL NEED TO BE REGISTERED TO ATTEND.

FULL PRESCRIBING INFORMATION FOR LUMASIRAN CAN BE ACCESSED HERE: HTTPS://WWW.EMA.EUROPA.EU/EN/DOCUMENTS/ PRODUCT-INFORMATION/OXLUMO-EPAR-PRODUCT-INFORMATION_EN.PDF. REGISTRATION CONDITIONS DIFFER INTERNATIONALLY; PLEASE REFER TO YOUR LOCAL PRESCRIBING INFORMATION FOR FURTHER INFORMATION.

JOIN US VIRTUALLY AT

ERA 2022FRIDAY, 20 MAY

13:30-14:30 (CEST)THIS SYMPOSIUM IS INITIATED, ORGANISED AND FUNDED BY

ALNYLAM PHARMACEUTICALSAGENDA AND FACULTY

WELCOME & INTRODUCTIONPROF. DR. JUSTINE BACCHETTA, HOSPICES CIVILS DE LYON / UNIVERSITE DE LYON, LYON, FRANCE

ROLE OF GENETIC TESTING IN THE DIAGNOSIS AND MANAGEMENT OF CKDPROF. DR. LAURENT MESNARD, SORBONNE UNIVERSITÉ, URGENCES NÉPHROLOGIQUES ET TRANSPLANTATION RÉNALE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, HÔPITAL TENON, PARIS, FRANCE

MANAGEMENT OF PRIMARY HYPEROXALURIA TYPE 1: WHAT’S NEW?DR SANDER GARRELFS, EMMA CHILDREN’S HOSPITAL, AMSTERDAM UMC, UNIVERSITY OF AMSTERDAM, NETHERLANDS

REAL-LIFE CASE EXPERIENCE IN PH1 MANAGEMENTPROF. DR. JUSTINE BACCHETTA, HOSPICES CIVILS DE LYON / UNIVERSITE DE LYON, LYON, FRANCE

Q&A

TO REPORT ADVERSE EVENTS PLEASE REFER TO YOUR LOCAL REPORTING GUIDELINES. OXL-CEMEA-00130 | MARCH 2022.


59TH


MAY 19-22, 2022

21


EBAC-ACCREDITED SYMPOSIUM TO BE HELD DURING ERA 2022, PARIS, FRANCE & VIRTUAL

AGENDA09:45 – 09:55 New insights and guidelines in managing patients

with CKD and diabetes: What are the challenges?

Johannes Mann, MD – Munich, Germany

09:55 – 10:10 Evolving science with GLP-1RA in CKD:

What is relevant for nephrology?

Filip Krag Knop, MD – Copenhagen, Denmark

10:10 – 10:25 GLP-1RA in clinical management of patients with CKD

and diabetes: Which patients will benefit?

Katherine Tuttle, MD – Spokane, WA, USA

10:25 – 10:45 Addressing the key challenges and opportunities

All faculty

SATURDAY, MAY 21, 2022 | 09:45 – 10:45 HRS | HALL N01Supported by an unrestricted educational grant from Novo Nordisk A/S.

The scientific programme has not been influenced in any way by its sponsor.

“In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which

might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant

to the event are declared to the audience prior to the CME activities.”

Preventing CKD in patients with diabetes - Exploring

the current and future roleof GLP-1RA


59TH


MAY 19-22, 2022

22



59TH


MAY 19-22, 2022

23


Interprofessional care management models, fostering the collaboration between nurses and physicians can have a positive impact on the provision of healthcare and on patient outcomes. The objective of this symposium is to present the physician’s, the nurse’s and the patient’s view in the context of a patient centric hemodialysis (HD) therapy. While all three stakeholders have the same overarching goal; to improve survival, to reduce complications and to improve patient’s quality of life, their clinical needs during the patient pathway and episode of care might be slightly different.

Therefore, starting from an enhanced classification of uremic molecules, this symposium Therefore, starting from an enhanced classification of uremic molecules, this symposium aims to highlight the impact of membrane innovation on the removal of larger middle molecules. The focus is on dialysis complication management and associated outcomes of many HD patients today such as quality of life and quality of care, symptom burden (such as pruritus) and associated conditions (like anemia), and medium to longer term outcomes such as cardiovascular events and hospitalizations.

The purpose is to highlight how HDx therapy has demonstrated to be impactful compared The purpose is to highlight how HDx therapy has demonstrated to be impactful compared with other HD treatments in improving quality of life and treatment and clinical outcomes in hemodialysis patients.

MCO delivering HDx therapy: improving clinical and economic outcomes in the real world

5 min

15 min

15 min

15 min

10 min

INTRODUCTION

Uremic toxins and inflammation

Impact on Hospitalizations and CV events

Improving pts reported outcomes and post-dialysis recovery time

Q&A

Prof. Mario Cozzolino, MD, PhD

Prof. Peter Stenvinkel, MD, PhD, FASN

Dr. Jernej Pajek, MD, PhD

Jarrin D. Penny RN, BSN

All

Time Topic Speaker

For more information visit us at our booth A240

JOIN OUR SYMPOSIUM

EMA-RC00-220007

MCO delivering HDx therapy:improving clinical and economic outcomesin the real world

21 May 2022 9:45 – 10:45 am

21 May 2022 9:45 – 10:45 am


59TH


MAY 19-22, 2022

24


A SHIFT IN FOCUSInternational insights into the optimal management of CKD-MBDSaturday 21 May 2022, 09.45–10.45 CEST, Room N04

Dear Colleague,

It is my pleasure to invite you to attend this Vifor Pharma-sponsored educational symposium, entitled ‘A shift in focus: international insights into the optimal management of CKD-MBD’.

The chronic kidney disease-mineral and bone disorder (CKD-MBD) continuum describes a multitude of complications that are a consequence of significant and abnormal alterations in mineral and bone parameters. There is an increased risk of morbidity and mortality across the CKD-MBD spectrum, particularly for patients with secondary hyperparathyroidism (SHPT) or hyperphosphataemia.

During this exciting, multimedia symposium, we will explore relevant and engaging patient cases that highlight and discuss possible solutions to the management challenges that still remain in these complex diseases, with the aim of improving therapeutic and patient outcomes. Through a combination of vibrant live Q&A discussions and pertinent clinical and real-world data, key concepts such as clear therapeutic target ranges, in particular levels of 25(OH)D, early intervention and sharing of phosphate management considerations will be examined by a renowned international faculty.

As we transition to the ‘new normal’, I am delighted to be welcoming you to this thought-provoking symposium in the ERA 2022 hybrid format, allowing colleagues from across the globe to discuss the common pitfalls of CKD-MBD management and real-world practical solutions to these hurdles.

Marianne Rix Chair

Date of preparation: March 2022MED-HQ-RAY-2200006

© 2022 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved.

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.Extended-release calcifediol is approved in Germany, Spain, Italy, Portugal, United Kingdom, Ireland, Netherlands, Sweden, Norway, Denmark, Switzerland, and Canada, but not in France. Materials related to this product shared at the symposium are not suitable for HCPs practising in France. Prescribing information varies per country. Before prescribing, always refer to the local SmPCs.Sucroferric oxyhydroxide is approved for use in Europe. Materials related to this product are intended for Healthcare Professionals from the United Kingdom and Europe excluding France. Approval conditions for products may vary from country to country. Before prescribing, always refer to the local SmPCs.

Sponsored by

Chair: Marianne Rix, Denmark

09.45 Welcome and introduction Marianne Rix, Denmark (Chair)

09.50 How high is high enough? 25(OH)D adequacy in non-dialysis CKD-MBD patients James Wetmore, USA and Jan Kielstein, Germany

Audience Q&A and discussion

10.15 Controlling serum phosphate levels: a focus on CKD patients on dialysis Jürgen Floege, Germany

Audience Q&A and discussion

10.40 Key takeaways from the panel and close All/Marianne Rix, Denmark (Chair)

AGENDAAGENDA

Click HERE or scan the QR code to register for ERA 22 and gain access to this interactive session. Please join us in a live Q&A following the presentations!

HERE

WELCOMEWELCOME

https://www.era-online.org/en/paris2022/registrazioni/


59TH


MAY 19-22, 2022

25


Saturday 21 May 202209:45–10:45 CEST Hall S01

Join Prof Claire Sharpe and colleagues for this independent symposium as they discuss how to reduce the burden of hyperkalemia whilst maintaining cardio-renal protection for people with chronic kidney disease.

Chaired by Claire Sharpe with Ellen Hoogeveen, Pantelis Sarafidis & David Thomas

AstraZeneca has provided an educational grant towards this independent program.

LEARNING OBJECTIVESAfter attending the symposium you will be able to:

1. Interpret K+ concentration alongside other patient risk- and clinical-based measures to inform hyperkalemia management and monitoring

2. Utilize the emerging evidence and guidelines for the optimization of RAASi therapy when risk of hyperkalemia is high

3. Explain the role of newer K+ binders in the management of hyperkalemia whilst maintaining cardio-renal protection

PROGRAM09:45 - 09:48 Introduction Claire Sharpe

King's College London, UK

09:48 - 10:03 Balancing cardio-renal protection and hyperkalemia risk in CKD

Pantelis SarafidisAristotle University of Thessaloniki, Greece

10:03 - 10:13 Hyperkalemia inpatient management and post-discharge: when should we use K+ binders?

David ThomasImperial College London, UK

10:43 - 10:45 Claire SharpeClose

Looking beyond K+ in hyperkalemia for cardio-renal protection

10:13 - 10:43 How can we reduce the burden of hyperkalemia?

Ellen HoogeveenJeroen Bosch Hospital, The Netherlands

Panel discussion and Q&A All (moderated by Claire Sharpe)

The symposium Looking beyond K+ in hyperkalemia for cardiorenal protection, Paris and online, France, 21/05/2022-21/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

INDEPENDENT CME-ACCREDITED SYMPOSIUM


59TH


MAY 19-22, 2022

26


JOIN THE MEDTRONIC SYMPOSIUM

Innovative treatment strategies for Haemodialysis and Hypertension

Saturday, May 21st

09:45–10:45 CETHall S02

Highlighting innovative solutions for the patient journey from hypertension to end stage renal disease:

• Renal denervation as an adjunctive treatment for hypertension, specifically focusing on CKD patients

• Novel therapies for ESRD patients to allow for a unique approach to fistula creation and preserving AV access

• Patient-centric solutions for dialysis access and treatment

09:45 – 09:50 Introduction & Objectives Prof. Roland E. Schmieder, Chairman (Germany)

09:50 –10:05 Advances in Hypertension Treatment: Patient Considerations for Renal Denervation Prof. Flavio Ribichini (Italy)

10:05 –10:13 Transform AV Fistula Creation with Ellipsys™ Vascular Access System Dr. Robert Shahverdyan (Germany)

10:13 –10:20 Preserving AV Access: Extending Fistula Longevity with IN.PACT™ Admiral™ DCB Prof. Raphael Coscas (France)

10:20 –10:27 Patient-centric solutions for dialysis access Dr. Francesca D’Ascenzo (Italy)

10:27–10:35 Patient-centric solutions for dialysis treatment Prof. Gaetano La Manna (Italy)

10:35 – 10:45 Key learnings & Conclusion All

Agenda

© 2022 Medtronic. 22-weu-era-2022-double-page-advert-in-industry-symposia-6566977

Prof. Schmieder

Prof. Ribichini

Dr. Shahverdyan

Prof. Coscas

Dr. D’Ascenzo

Prof. La Manna


59TH


MAY 19-22, 2022

27



59TH


MAY 19-22, 2022

28


COPYRIGHT© 2022 Toray Medical Company Limited

Supported by

Prof. Laurent JuillardHospital Universitaire Edouard Herriot /Lyon, France

“À la carte” Hemodialysis for Patient:

PMMA Adsorptive Membrane

EDTA 2022 –Paris Industry Symposia

Date: May 21st (SAT), 2022Time: 09:45 am – 10:45 am (Total time: 60 min)

Room: Virtual Hall 1

Chairman

Speakers Dr. Ikuto MasakaneYabuki Hospital /Yamagata, Japan“PMMA could be “Hors-d’oeuvre” or “Plat (principal)” ?”

Dr. Paolo FabbriniASST Nord Milano Ospedale /Milano, Italy“PBUT and inflammation process in HD patients: pos-sible role for Adsorption Hemodiafiltration”

Prof. Giuseppe CastellanoUniversita’ Degli Studi Di Milano /Milano, Italy“Enhancing Immune Protection in HD patients: role of PMMA membrane.”


59TH


MAY 19-22, 2022

29


This is an AstraZeneca-sponsored, non-promotional scientific exchange symposium

The presentation will be followed by a live Q&A session moderated by Professor Philippe Gatault with presenters

Professors Claudio Ronco and Hugh Montgomery

Please join us during the 59th ERA Congress in Paris, Franceand virtually for a discussion entitled:

Kidney disease and COVID-19: addressing challenges to protect

the vulnerable

Saturday 21 May 202213:30–14:30 CESTParis Convention CentreParis, France

© 2022 AstraZeneca. All rights reserved. Vault ID: FR-11535; Date of Preparation: April 2022

This presentation is supported by and made on behalf of AstraZeneca. This program is not certified for continuing education credit (non-CE).

This AstraZeneca-sponsored scientific-exchange symposium brings together global experts to provide delegates with an overview of the impact of COVID-19 on patients with kidney disease.

The speakers will reflect on the challenges experienced during the pandemic, particularly among the most vulnerable populations and those who may have a suboptimal vaccine response. They will discuss the latest approaches to protecting these populations, including any new therapies for the prevention of COVID-19.

The session will conclude with a live panel discussion, inviting the audience to share any questions.

© 2022 AstraZeneca. All rights reserved. Vault ID: FR-11535; Date of Preparation: April 2022

Philippe Gatault, MDRenal Transplant Unit, CHU Tours Tours, FranceOpening remarks: The impact of COVID-19 on patientswith kidney disease

Hugh Montgomery, OBE, MB.BS, BSc, FRCP, MD, FRSB, FFICM, FRIProfessor of Intensive Care Medicine, University College LondonLondon, EnglandProtecting the vulnerable: COVID-19 prevention strategiesfor high-risk patients

Claudio Ronco, MDSenior Lecturer and Professor, University of PadovaDirector, International Renal Research Institute of VicenzaSan Bartolo HospitalVicenza, ItalyKidney disease and COVID-19: exploring challenges andunmet needs


59TH


MAY 19-22, 2022

30


Nonsteroidal MRAs:A new hope for improved cardiorenal outcomes in patients with CKD and T2DSaturday 21 May 2022 | 13:30–14:30 CEST

Symposium sponsored by Bayer

59th ERA Congress Room N02, Paris Expo Porte de VersaillesAlso available online – live and on-demand (session ISS 2.11)

On behalf of the faculty, I invite you to join our speakers to gain expert insights on how the latest evidence on non-steroidal mineralocorticoid receptor antagonists can be applied to improve outcomes in patients with chronic kidney disease and type 2 diabetes, and on the importance of early diagnosis and personalised treatment regimens.

Patrick Rossignol (Chair)

© 2022 Bayer AG, March 2022 MA-M_FIN-ALL-0734-1, MA-M_FIN-FR-0109-1

13:30–13:35 Welcome and introduction

13:35–13:50 CKD in T2D: How urgently do we heed the call for treatment?

13:50–14:05 Cardiorenal protection in patients with CKD and T2D: From FIDELIO-DKD to FIDELITY

14:05–14:20 Nonsteroidal MRAs in clinical practice: Whom to treat, when and how

Q&A14:20–14:30

Summary and close

Patrick Rossignol

Jolanta Małyszko

Roland Schmieder

George Bakris

All facultyModerated by Patrick Rossignol

Patrick Rossignol

Patrick RossignolChair (France)

Jolanta Małyszko(Poland)

George Bakris(USA) (Germany)

Roland Schmieder

Visit the Bayer Medical booth for more information


59TH


MAY 19-22, 2022

31


Date of preparation: March 2022HQ-DFK-2200068

© 2022 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.

Difelikefalin is approved for use in Europe. Materials related to this product are intended for Healthcare Professionals from Europe excluding France.Approval conditions for products may vary from country to country. Before prescribing, always refer to the local SmPCs.

Sponsored by

Welcome and introduction Edwina Brown, UK (Chair)

Exploring symptom burden in haemodialysis patients Marc Vervloet, The Netherlands

Uncovering the complexities of CKD-aP Vincent Brandenburg, Germany

Evolving management horizons in CKD-aP Kam Kalantar-Zadeh, USA

Audience Q&A All

Summary and meeting close Edwina Brown, UK (Chair)

PROGRAMME

The burden and management of symptoms in chronic kidney disease (CKD) patients on haemodialysis: an insight into CKD-associated pruritusChair: Edwina Brown, UK Saturday 21 May 2022, 13.30–14.30 CESTRoom N03, Paris Expo Porte de Versailles, FranceDear Colleague,

It is my pleasure to invite you to attend this Vifor Pharma-sponsored educational symposium, entitled ‘The burden and management of symptoms in chronic kidney disease (CKD) patients on haemodialysis: an insight into CKD-associated pruritus’. People with CKD on haemodialysis experience a range of symptoms that impact on their quality of life (QoL), sleep, ability to work and on their clinical outcomes. In the symposium, we will discuss the importance of recognising symptom burden and assessing symptoms regularly, and consider what opportunities exist for improving symptom management.

CKD-associated pruritus (CKD-aP) is an important yet under-reported and under-recognised symptom that can have a significant impact on the QoL and clinical outcomes of people with CKD. The symposium will provide insights into the unmet needs, clinical aspects and pathophysiology of CKD-aP, before moving on to give an in-depth assessment of the evolving diagnosis and treatment landscape.

We look forward to you joining us for this exciting and educational symposium.

Professor Edwina Brown Chair

to submit your topical points for discussion and questions ahead of the live event. Questions submitted live will also be addressed during the Q&A session of the symposium.

Click HERE or scan the QR code

LUNCH TO BE PROVIDED

http://www.surveymonkey.co.uk/r/ViforCKD-aPERA


59TH


MAY 19-22, 2022

32


HIF-PH inhibition: Simplicity through innovation for adult patients with anaemia of CKDERA industry-sponsored symposium Saturday 21 May, 13:30–14:30 CEST | Room number N04, Paris Convention Centre Live-streamed on the ERA Congress platform

Live interactive presentations, led by the experts:

Symposium Agenda

© 2022 Astellas Pharma Europe Ltd. Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc. CKD, chronic kidney disease; HIF, hypoxia-inducible factor.NEPH_2022_0033_ABC | Date of preparation: April 2022 | Expiry date: April 2024

13:30–13:31 | Welcome and introductions PROFESSOR DENIS FOUQUE, CHAIRPERSON

13:31–13:34 | Living with anaemia of CKD: the patient experience VIDEO

13:34–13:40 | The journey so far: history of treatment and current guidelines PROFESSOR DENIS FOUQUE

13:40–14:15 | HIF activation: a coordinated approach to the management of anaemia of CKD PROFESSOR DANILO FLISER & PROFESSOR SUNIL BHANDARI

14:15–14:20 | Real world: patient case study experience PROFESSOR MASAOMI NANGAKU (VIDEO)

14:20–14:30 | Q&A PROFESSOR DENIS FOUQUE

Professor Sunil BhandariHull and East Yorkshire NHS Trust, United Kingdom

Professor Danilo FliserSaarland University Medical Center, Germany

Professor Masaomi NangakuUniversity of Tokyo School of Medicine, Japan

Professor Denis FouqueClaude Bernard University Lyon and Lyon Sud Hospital Center, France

Symposium intended for an international audience, organised by Astellas Pharma Europe Ltd.

Come and hear our expert speakers at the in-person Astellas booth, at location D.360!Astellas is delighted that we will be joined at our booth by a group of expert speakers who will cover a number of topical subjects including: COVID and the value of keeping patients out of the hospital, and targeting the HIF pathway for the treatment of adult patients with anaemia of CKD.

Friday 20 May

Saturday 21 May

Don’t forget you can also visit our virtual boothby logging into the ERA congress website

PROFESSOR GABRIEL CHOUKROUN10:15–10:30 | HIF-PH inhibition: a new coordinated approach to the management of anaemia of CKD

11:30–11:45 | Addressing the unmet needs of our patients with anaemia of CKD

PROFESSOR SUNIL BHANDARI16:40–16:55 | Keeping patients with CKD out of hospital: lessons from the COVID pandemic

PROFESSOR ROBERTO MINUTOLO 10:15–10:30 | EVRENZO: clinical benefits of a novel mechanism of action

PROFESSOR JONATHAN BARRATT17:00–17:15 | Initiating treatment with EVRENZO: practical considerations

PROFESSOR DANILO FLISER16:45–17:00 | EVRENZO: clinical data from the phase 3 ALPINE development programme

Intended for an international audience – not intended for French healthcare professionals © 2022 Astellas Pharma Europe Ltd. Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc. CKD, chronic kidney disease; HIF, hypoxia-inducible factor. NEPH_2022_0033_ABC | Date of preparation: April 2022 | Expiry date: April 2024 For more information, please consult the complete product information for EVRENZO (EMA). To access it, please scan the QR code or click here.


59TH


MAY 19-22, 2022

33


AGENDATIME TITLE SPEAKER

Understanding the clinical heterogeneity in females with Fabry disease: the impact of genotype, phenotype and X-chromosome inactivation

13:30 – 13:40

13:40 – 13:55

Q&A and panel discussion

Challenging the myths and confronting the realities in the management of female patients with Fabry disease

13:55 – 14:10

14:10 – 14:25

Conclusion and take-home messages14:25 – 14:30

Welcome and introduction Gabriel Choukroun (France)

Aleš Linhart (Czech Republic)

Roser Torra (Spain)

All

Gabriel Choukroun (France)

A Sanofi-sponsored symposium Sanofi Booth B100 - Hall B

MAT-GLB-2200861(v1.0) | March 2022Copyright © 2022 Sanofi. All rights reserved

Managing female patients with Fabry disease – the relevance of the factor Professor Gabriel Choukroun

Centre Hospitalier Universitaire, Amiens, France

Professor Roser TorraAutonomous University of

Barcelona, Barcelona, Spain

Professor Aleš Linhart Charles University,

Prague, Czech Republic

SATURDAY21 MAY, 202213:30–14:30 (CET)Room S01


59TH


MAY 19-22, 2022

34



59TH


MAY 19-22, 2022

35


Diagnosis and Management of aHUS: Time is of the Essence

Hybrid satellite symposium Saturday 21 May 2022, 13:30–14:30 CET

Room S03, Paris Expo Porte de Versailles and Virtual

Alexion, AstraZeneca Rare Disease Satellite Symposium59th Annual Scientific Meeting

The European Renal Association

FacultyProf Alberto Ortiz, Madrid, Spain (Chair)

Dr Samir V Parikh, Ohio, USADr Giorgia Comai, Bologna, Italy

This symposium is fully funded and organised by Alexion, AstraZeneca Rare Disease. Alexion, AstraZeneca Rare Disease products will be discussed at this event. This event is intended for healthcare professionals only.

Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA.

M/INT/SOL-a/0027 April 2022

aHUS, atypical haemolytic uraemic syndrome

Alexion Pharmaceuticals, Inc.121 Seaport Boulevard, Boston, MA 02210

This symposium is fully funded and organised by Alexion, AstraZeneca Rare Disease. Alexion, AstraZeneca Rare Disease products will be discussed at this event. This event is intended for healthcare professionals only.

Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA.

Dear Congress Attendee,

It is our great pleasure to invite you to attend the Alexion, AstraZeneca Rare Disease-sponsored satellite symposium at the 59th annual scientific meeting of the European Renal Association.

Diagnosis and Management of aHUS: Time is of the Essence

During this symposium, the faculty will:

• Discuss factors which complicate diagnosis of aHUS, such as a lack of confirmatory tests and presence of associated conditions, the consequences of delayed diagnosis, and approaches to aid in a timely diagnosis

• Discuss aHUS-associated clinical events, conditions and triggers as key factors in delayed diagnoses, as illustrated by case studies

• Highlight current practice and unmet needs in the management of aHUS, particularly in the presence of associated events, conditions and/or triggers, alongside patient types suited for treatment

• Host an open Q&A panel discussion, offering an opportunity to ask experts and exchange ideas on the effective identification and management of patients with aHUS.

We look forward to your active participation in this educational meeting.

Programme

Welcome and introduction Prof Alberto Ortiz, Madrid, Spain

aHUS, Causes and Effects of Delayed Diagnosis Prof Alberto Ortiz, Madrid, Spain

aHUS, Associated Conditions Muddy the Water Dr Samir V Parikh, Ohio, USA

aHUS Management, Navigating Muddy Waters Dr Giorgia Comai, Bologna, Italy

Q&A Panel Session Prof Alberto Ortiz, Madrid, Spain Dr Samir V Parikh, Ohio, USA Dr Giorgia Comai, Bologna, Italy

Please visit the Alexion team at the medical booth for more information.


59TH


MAY 19-22, 2022

36


Saturday May 21st 13.30-14.30 CET

Live Symposium in Hall N02held during the 59th ERA Congress

HQ-AVA-2200053 Date of approval March 2022

A Virtual Symposium held during the 59th ERA Congress The multiple faces

of ANCA vasculitisChair: Prof. Dr. med. Hermann Haller

Hannover Medical School, Germany

AGENDA

13.50 ANCA vasculitis from a different angle: Ear and nose involvement in a patient with AAVDr. Marcos Martinez Del Pero, Bury St. Edmunds, UK

14.05 What we need to know about central nervous involvement in ANCA vasculitisProf. Dr. med. Bernhard Hellmich, Kirchheim unter Teck, Germany

14.20-14.30 Q&A and Closing remarksProf. Dr. med. Hermann Haller

13.30 Welcome and introductionsProf. Dr. med. Hermann Haller

13.35 Remission and relapse in ANCA-associated vasculitis: What does success look like? Prof. Noémie Jourde-Chiche, Marseille, France


59TH


MAY 19-22, 2022

37


Introducing

Nipro’s novel super high flux sharp cut-off dialyzer

Join us at an

interactive ERA industry symposiumSaturday 21st May 2022 | 13:30-14:30 (CET)

Objectives of the symposium: Discovering state-of-the-art membrane designs and the clinical data on their associated survival in large cohorts

•Discovering the clinical impact of the middle molecule uremic toxins on patients’ morbidity and mortality

•Exploring the clinical findings on the performance and safety of the super high flux sharp cut-off Elisio-HX

membrane vs high flux and medium cut-off membranes

PROF. ANDREW DAVENPORTUCL center for Nephrology, Royal Free Hospital, the UK

PROF. ABE MASANORIDivision of Nephrology, Nihon University School of Medicine, Japan

PROF. VINCENZO PANICHIDivision of Nephrology, Versilia Hospital, Italy

PROF. FRANCISCO MADUELLDivision of Nephrology, Hospital Clinic Barcelona, Spain

13:30-13:35Welcome and introduction

13:35-13:50Super high flux dialyzers and their associated

survival in dialysis patients

13:50-14:05The impact of middle molecule uremic toxins

on clinical outcomes of dialysis patients

14:05-14:25Evaluation and comparison of Elisio-HX

versus HD, HDx, and HDF dialyzers

14:25-14:30Live Q&A

This symposium is sponsored by: NIPRO Medical Europe N.V. | www.nipro-group.com

Program


congress - european renal association

Documents